nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—MAP3K19—female reproductive system—fallopian tube cancer	0.00279	0.00279	CbGeAlD
Bosutinib—ULK3—uterine cervix—fallopian tube cancer	0.00279	0.00279	CbGeAlD
Bosutinib—MAP2K2—uterine cervix—fallopian tube cancer	0.00279	0.00279	CbGeAlD
Bosutinib—MAP3K2—uterine cervix—fallopian tube cancer	0.00277	0.00277	CbGeAlD
Bosutinib—CAMK2G—endometrium—fallopian tube cancer	0.00276	0.00276	CbGeAlD
Bosutinib—BMP2K—endometrium—fallopian tube cancer	0.00276	0.00276	CbGeAlD
Bosutinib—STK4—female gonad—fallopian tube cancer	0.00274	0.00274	CbGeAlD
Bosutinib—MAP3K7—uterine cervix—fallopian tube cancer	0.00274	0.00274	CbGeAlD
Bosutinib—TNK2—female reproductive system—fallopian tube cancer	0.00274	0.00274	CbGeAlD
Bosutinib—PTK2—epithelium—fallopian tube cancer	0.00273	0.00273	CbGeAlD
Bosutinib—MAP4K4—uterus—fallopian tube cancer	0.00273	0.00273	CbGeAlD
Bosutinib—LRRK2—endometrium—fallopian tube cancer	0.00273	0.00273	CbGeAlD
Bosutinib—BCR—uterus—fallopian tube cancer	0.00271	0.00271	CbGeAlD
Bosutinib—TBK1—uterine cervix—fallopian tube cancer	0.00271	0.00271	CbGeAlD
Bosutinib—PTK2—uterine cervix—fallopian tube cancer	0.00271	0.00271	CbGeAlD
Bosutinib—CAMK1D—female gonad—fallopian tube cancer	0.00271	0.00271	CbGeAlD
Bosutinib—MAP4K2—female reproductive system—fallopian tube cancer	0.0027	0.0027	CbGeAlD
Bosutinib—CAMK1D—vagina—fallopian tube cancer	0.00269	0.00269	CbGeAlD
Bosutinib—STK24—female gonad—fallopian tube cancer	0.00268	0.00268	CbGeAlD
Bosutinib—STK24—vagina—fallopian tube cancer	0.00266	0.00266	CbGeAlD
Bosutinib—ERBB4—female reproductive system—fallopian tube cancer	0.00266	0.00266	CbGeAlD
Bosutinib—STK3—female reproductive system—fallopian tube cancer	0.00266	0.00266	CbGeAlD
Bosutinib—IRAK1—uterine cervix—fallopian tube cancer	0.00266	0.00266	CbGeAlD
Bosutinib—RPS6KB1—epithelium—fallopian tube cancer	0.00263	0.00263	CbGeAlD
Bosutinib—ROCK1—female reproductive system—fallopian tube cancer	0.00263	0.00263	CbGeAlD
Bosutinib—CSK—uterus—fallopian tube cancer	0.00262	0.00262	CbGeAlD
Bosutinib—CSNK1E—endometrium—fallopian tube cancer	0.00262	0.00262	CbGeAlD
Bosutinib—RPS6KB1—uterine cervix—fallopian tube cancer	0.00261	0.00261	CbGeAlD
Bosutinib—CSNK1A1—uterus—fallopian tube cancer	0.00261	0.00261	CbGeAlD
Bosutinib—LCK—uterine cervix—fallopian tube cancer	0.00259	0.00259	CbGeAlD
Bosutinib—FER—female gonad—fallopian tube cancer	0.00259	0.00259	CbGeAlD
Bosutinib—TYRO3—female gonad—fallopian tube cancer	0.00259	0.00259	CbGeAlD
Bosutinib—HCK—uterus—fallopian tube cancer	0.00259	0.00259	CbGeAlD
Bosutinib—CLK1—uterus—fallopian tube cancer	0.00259	0.00259	CbGeAlD
Bosutinib—AXL—uterine cervix—fallopian tube cancer	0.00258	0.00258	CbGeAlD
Bosutinib—SIK1—endometrium—fallopian tube cancer	0.00258	0.00258	CbGeAlD
Bosutinib—IRAK4—endometrium—fallopian tube cancer	0.00258	0.00258	CbGeAlD
Bosutinib—FER—vagina—fallopian tube cancer	0.00258	0.00258	CbGeAlD
Bosutinib—EPHA5—vagina—fallopian tube cancer	0.00258	0.00258	CbGeAlD
Bosutinib—BMPR2—female reproductive system—fallopian tube cancer	0.00255	0.00255	CbGeAlD
Bosutinib—CAMK2G—uterus—fallopian tube cancer	0.00254	0.00254	CbGeAlD
Bosutinib—EPHB3—female reproductive system—fallopian tube cancer	0.00253	0.00253	CbGeAlD
Bosutinib—STK36—female reproductive system—fallopian tube cancer	0.00253	0.00253	CbGeAlD
Bosutinib—BTK—female gonad—fallopian tube cancer	0.00253	0.00253	CbGeAlD
Bosutinib—MAP4K1—vagina—fallopian tube cancer	0.00252	0.00252	CbGeAlD
Bosutinib—MAP2K2—endometrium—fallopian tube cancer	0.00252	0.00252	CbGeAlD
Bosutinib—ULK3—endometrium—fallopian tube cancer	0.00252	0.00252	CbGeAlD
Bosutinib—BTK—vagina—fallopian tube cancer	0.00251	0.00251	CbGeAlD
Bosutinib—EGFR—uterus—fallopian tube cancer	0.00251	0.00251	CbGeAlD
Bosutinib—TNK2—female gonad—fallopian tube cancer	0.00249	0.00249	CbGeAlD
Bosutinib—EPHB4—epithelium—fallopian tube cancer	0.00249	0.00249	CbGeAlD
Bosutinib—SLK—uterine cervix—fallopian tube cancer	0.00249	0.00249	CbGeAlD
Bosutinib—MAP3K7—endometrium—fallopian tube cancer	0.00248	0.00248	CbGeAlD
Bosutinib—EPHB4—uterine cervix—fallopian tube cancer	0.00247	0.00247	CbGeAlD
Bosutinib—MAP4K4—female reproductive system—fallopian tube cancer	0.00246	0.00246	CbGeAlD
Bosutinib—MAP4K2—female gonad—fallopian tube cancer	0.00246	0.00246	CbGeAlD
Bosutinib—TBK1—endometrium—fallopian tube cancer	0.00245	0.00245	CbGeAlD
Bosutinib—EPHA2—epithelium—fallopian tube cancer	0.00244	0.00244	CbGeAlD
Bosutinib—MAP4K2—vagina—fallopian tube cancer	0.00244	0.00244	CbGeAlD
Bosutinib—BCR—female reproductive system—fallopian tube cancer	0.00244	0.00244	CbGeAlD
Bosutinib—STK3—female gonad—fallopian tube cancer	0.00242	0.00242	CbGeAlD
Bosutinib—MAP3K12—female reproductive system—fallopian tube cancer	0.00242	0.00242	CbGeAlD
Bosutinib—EPHA2—uterine cervix—fallopian tube cancer	0.00242	0.00242	CbGeAlD
Bosutinib—FYN—uterine cervix—fallopian tube cancer	0.00242	0.00242	CbGeAlD
Bosutinib—CSNK1E—uterus—fallopian tube cancer	0.00241	0.00241	CbGeAlD
Bosutinib—STK3—vagina—fallopian tube cancer	0.00241	0.00241	CbGeAlD
Bosutinib—ERBB4—vagina—fallopian tube cancer	0.00241	0.00241	CbGeAlD
Bosutinib—ROCK1—female gonad—fallopian tube cancer	0.00239	0.00239	CbGeAlD
Bosutinib—SIK1—uterus—fallopian tube cancer	0.00238	0.00238	CbGeAlD
Bosutinib—MAP2K1—female reproductive system—fallopian tube cancer	0.00237	0.00237	CbGeAlD
Bosutinib—STK35—female reproductive system—fallopian tube cancer	0.00237	0.00237	CbGeAlD
Bosutinib—MAP4K5—uterine cervix—fallopian tube cancer	0.00236	0.00236	CbGeAlD
Bosutinib—MAP3K3—uterine cervix—fallopian tube cancer	0.00236	0.00236	CbGeAlD
Bosutinib—RPS6KB1—endometrium—fallopian tube cancer	0.00236	0.00236	CbGeAlD
Bosutinib—CSK—female reproductive system—fallopian tube cancer	0.00236	0.00236	CbGeAlD
Bosutinib—EPHA4—uterus—fallopian tube cancer	0.00235	0.00235	CbGeAlD
Bosutinib—FGR—endometrium—fallopian tube cancer	0.00234	0.00234	CbGeAlD
Bosutinib—CSNK1A1—female reproductive system—fallopian tube cancer	0.00234	0.00234	CbGeAlD
Bosutinib—AXL—endometrium—fallopian tube cancer	0.00234	0.00234	CbGeAlD
Bosutinib—ERBB3—uterus—fallopian tube cancer	0.00233	0.00233	CbGeAlD
Bosutinib—CLK1—female reproductive system—fallopian tube cancer	0.00233	0.00233	CbGeAlD
Bosutinib—MAP2K2—uterus—fallopian tube cancer	0.00232	0.00232	CbGeAlD
Bosutinib—ULK3—uterus—fallopian tube cancer	0.00232	0.00232	CbGeAlD
Bosutinib—BMPR2—female gonad—fallopian tube cancer	0.00232	0.00232	CbGeAlD
Bosutinib—BMPR2—vagina—fallopian tube cancer	0.00231	0.00231	CbGeAlD
Bosutinib—MAP3K2—uterus—fallopian tube cancer	0.00231	0.00231	CbGeAlD
Bosutinib—STK36—female gonad—fallopian tube cancer	0.0023	0.0023	CbGeAlD
Bosutinib—EPHB3—female gonad—fallopian tube cancer	0.0023	0.0023	CbGeAlD
Bosutinib—STK36—vagina—fallopian tube cancer	0.00229	0.00229	CbGeAlD
Bosutinib—EPHB3—vagina—fallopian tube cancer	0.00229	0.00229	CbGeAlD
Bosutinib—MAP3K7—uterus—fallopian tube cancer	0.00229	0.00229	CbGeAlD
Bosutinib—BMP2K—female reproductive system—fallopian tube cancer	0.00228	0.00228	CbGeAlD
Bosutinib—CAMK2G—female reproductive system—fallopian tube cancer	0.00228	0.00228	CbGeAlD
Bosutinib—MERTK—female gonad—fallopian tube cancer	0.00228	0.00228	CbGeAlD
Bosutinib—MERTK—vagina—fallopian tube cancer	0.00226	0.00226	CbGeAlD
Bosutinib—LRRK2—female reproductive system—fallopian tube cancer	0.00226	0.00226	CbGeAlD
Bosutinib—PTK2—uterus—fallopian tube cancer	0.00226	0.00226	CbGeAlD
Bosutinib—SLK—endometrium—fallopian tube cancer	0.00225	0.00225	CbGeAlD
Bosutinib—MAP4K4—female gonad—fallopian tube cancer	0.00224	0.00224	CbGeAlD
Bosutinib—EPHB4—endometrium—fallopian tube cancer	0.00223	0.00223	CbGeAlD
Bosutinib—MAP4K4—vagina—fallopian tube cancer	0.00222	0.00222	CbGeAlD
Bosutinib—NUAK2—female gonad—fallopian tube cancer	0.00222	0.00222	CbGeAlD
Bosutinib—BCR—female gonad—fallopian tube cancer	0.00222	0.00222	CbGeAlD
Bosutinib—NUAK2—vagina—fallopian tube cancer	0.00221	0.00221	CbGeAlD
Bosutinib—BCR—vagina—fallopian tube cancer	0.00221	0.00221	CbGeAlD
Bosutinib—PTK2B—female reproductive system—fallopian tube cancer	0.00221	0.00221	CbGeAlD
Bosutinib—MAP3K12—female gonad—fallopian tube cancer	0.0022	0.0022	CbGeAlD
Bosutinib—MAP3K12—vagina—fallopian tube cancer	0.00219	0.00219	CbGeAlD
Bosutinib—EPHA2—endometrium—fallopian tube cancer	0.00219	0.00219	CbGeAlD
Bosutinib—FYN—endometrium—fallopian tube cancer	0.00219	0.00219	CbGeAlD
Bosutinib—YES1—uterine cervix—fallopian tube cancer	0.00218	0.00218	CbGeAlD
Bosutinib—CSNK1E—female reproductive system—fallopian tube cancer	0.00217	0.00217	CbGeAlD
Bosutinib—STK10—uterine cervix—fallopian tube cancer	0.00216	0.00216	CbGeAlD
Bosutinib—LCK—uterus—fallopian tube cancer	0.00216	0.00216	CbGeAlD
Bosutinib—MAP2K1—female gonad—fallopian tube cancer	0.00216	0.00216	CbGeAlD
Bosutinib—STK35—female gonad—fallopian tube cancer	0.00216	0.00216	CbGeAlD
Bosutinib—TAOK3—uterine cervix—fallopian tube cancer	0.00215	0.00215	CbGeAlD
Bosutinib—AXL—uterus—fallopian tube cancer	0.00215	0.00215	CbGeAlD
Bosutinib—STK35—vagina—fallopian tube cancer	0.00215	0.00215	CbGeAlD
Bosutinib—CSK—female gonad—fallopian tube cancer	0.00215	0.00215	CbGeAlD
Bosutinib—SIK1—female reproductive system—fallopian tube cancer	0.00214	0.00214	CbGeAlD
Bosutinib—MAP4K5—endometrium—fallopian tube cancer	0.00214	0.00214	CbGeAlD
Bosutinib—MAP3K3—endometrium—fallopian tube cancer	0.00214	0.00214	CbGeAlD
Bosutinib—CSK—vagina—fallopian tube cancer	0.00213	0.00213	CbGeAlD
Bosutinib—CSNK1A1—female gonad—fallopian tube cancer	0.00213	0.00213	CbGeAlD
Bosutinib—CSNK1A1—vagina—fallopian tube cancer	0.00212	0.00212	CbGeAlD
Bosutinib—HCK—female gonad—fallopian tube cancer	0.00212	0.00212	CbGeAlD
Bosutinib—CLK1—female gonad—fallopian tube cancer	0.00212	0.00212	CbGeAlD
Bosutinib—SRC—epithelium—fallopian tube cancer	0.00212	0.00212	CbGeAlD
Bosutinib—EPHA4—female reproductive system—fallopian tube cancer	0.00212	0.00212	CbGeAlD
Bosutinib—CLK1—vagina—fallopian tube cancer	0.0021	0.0021	CbGeAlD
Bosutinib—HCK—vagina—fallopian tube cancer	0.0021	0.0021	CbGeAlD
Bosutinib—ABL2—female gonad—fallopian tube cancer	0.0021	0.0021	CbGeAlD
Bosutinib—SRC—uterine cervix—fallopian tube cancer	0.0021	0.0021	CbGeAlD
Bosutinib—ERBB3—female reproductive system—fallopian tube cancer	0.00209	0.00209	CbGeAlD
Bosutinib—ABL2—vagina—fallopian tube cancer	0.00209	0.00209	CbGeAlD
Bosutinib—ULK3—female reproductive system—fallopian tube cancer	0.00209	0.00209	CbGeAlD
Bosutinib—MAP2K2—female reproductive system—fallopian tube cancer	0.00209	0.00209	CbGeAlD
Bosutinib—BMP2K—female gonad—fallopian tube cancer	0.00208	0.00208	CbGeAlD
Bosutinib—CAMK2G—female gonad—fallopian tube cancer	0.00208	0.00208	CbGeAlD
Bosutinib—MAP3K2—female reproductive system—fallopian tube cancer	0.00207	0.00207	CbGeAlD
Bosutinib—SLK—uterus—fallopian tube cancer	0.00207	0.00207	CbGeAlD
Bosutinib—BMP2K—vagina—fallopian tube cancer	0.00207	0.00207	CbGeAlD
Bosutinib—CAMK2G—vagina—fallopian tube cancer	0.00207	0.00207	CbGeAlD
Bosutinib—LRRK2—female gonad—fallopian tube cancer	0.00206	0.00206	CbGeAlD
Bosutinib—EPHB4—uterus—fallopian tube cancer	0.00206	0.00206	CbGeAlD
Bosutinib—EGFR—female gonad—fallopian tube cancer	0.00205	0.00205	CbGeAlD
Bosutinib—LRRK2—vagina—fallopian tube cancer	0.00205	0.00205	CbGeAlD
Bosutinib—PTK2—female reproductive system—fallopian tube cancer	0.00203	0.00203	CbGeAlD
Bosutinib—TBK1—female reproductive system—fallopian tube cancer	0.00203	0.00203	CbGeAlD
Bosutinib—FYN—uterus—fallopian tube cancer	0.00201	0.00201	CbGeAlD
Bosutinib—PTK2B—female gonad—fallopian tube cancer	0.00201	0.00201	CbGeAlD
Bosutinib—PTK2B—vagina—fallopian tube cancer	0.002	0.002	CbGeAlD
Bosutinib—IRAK1—female reproductive system—fallopian tube cancer	0.00199	0.00199	CbGeAlD
Bosutinib—CSNK1E—female gonad—fallopian tube cancer	0.00198	0.00198	CbGeAlD
Bosutinib—YES1—endometrium—fallopian tube cancer	0.00197	0.00197	CbGeAlD
Bosutinib—MAP4K5—uterus—fallopian tube cancer	0.00197	0.00197	CbGeAlD
Bosutinib—CSNK1E—vagina—fallopian tube cancer	0.00196	0.00196	CbGeAlD
Bosutinib—RPS6KB1—female reproductive system—fallopian tube cancer	0.00195	0.00195	CbGeAlD
Bosutinib—TAOK3—endometrium—fallopian tube cancer	0.00195	0.00195	CbGeAlD
Bosutinib—SIK1—female gonad—fallopian tube cancer	0.00194	0.00194	CbGeAlD
Bosutinib—IRAK4—female gonad—fallopian tube cancer	0.00194	0.00194	CbGeAlD
Bosutinib—FGR—female reproductive system—fallopian tube cancer	0.00194	0.00194	CbGeAlD
Bosutinib—AXL—female reproductive system—fallopian tube cancer	0.00193	0.00193	CbGeAlD
Bosutinib—IRAK4—vagina—fallopian tube cancer	0.00193	0.00193	CbGeAlD
Bosutinib—MAP2K5—uterine cervix—fallopian tube cancer	0.00193	0.00193	CbGeAlD
Bosutinib—EPHA4—female gonad—fallopian tube cancer	0.00192	0.00192	CbGeAlD
Bosutinib—EPHA4—vagina—fallopian tube cancer	0.00191	0.00191	CbGeAlD
Bosutinib—ERBB3—female gonad—fallopian tube cancer	0.00191	0.00191	CbGeAlD
Bosutinib—MAP2K2—female gonad—fallopian tube cancer	0.0019	0.0019	CbGeAlD
Bosutinib—ULK3—female gonad—fallopian tube cancer	0.0019	0.0019	CbGeAlD
Bosutinib—ULK3—vagina—fallopian tube cancer	0.00189	0.00189	CbGeAlD
Bosutinib—MAP3K2—female gonad—fallopian tube cancer	0.00189	0.00189	CbGeAlD
Bosutinib—CSF1R—uterine cervix—fallopian tube cancer	0.00188	0.00188	CbGeAlD
Bosutinib—MAP3K7—female gonad—fallopian tube cancer	0.00187	0.00187	CbGeAlD
Bosutinib—MAP3K7—vagina—fallopian tube cancer	0.00186	0.00186	CbGeAlD
Bosutinib—EPHB4—female reproductive system—fallopian tube cancer	0.00185	0.00185	CbGeAlD
Bosutinib—TBK1—female gonad—fallopian tube cancer	0.00185	0.00185	CbGeAlD
Bosutinib—PTK2—female gonad—fallopian tube cancer	0.00185	0.00185	CbGeAlD
Bosutinib—PTK2—vagina—fallopian tube cancer	0.00184	0.00184	CbGeAlD
Bosutinib—TBK1—vagina—fallopian tube cancer	0.00184	0.00184	CbGeAlD
Bosutinib—YES1—uterus—fallopian tube cancer	0.00182	0.00182	CbGeAlD
Bosutinib—EPHA2—female reproductive system—fallopian tube cancer	0.00181	0.00181	CbGeAlD
Bosutinib—IRAK1—female gonad—fallopian tube cancer	0.00181	0.00181	CbGeAlD
Bosutinib—FYN—female reproductive system—fallopian tube cancer	0.00181	0.00181	CbGeAlD
Bosutinib—STK10—uterus—fallopian tube cancer	0.0018	0.0018	CbGeAlD
Bosutinib—TAOK3—uterus—fallopian tube cancer	0.00179	0.00179	CbGeAlD
Bosutinib—RPS6KB1—female gonad—fallopian tube cancer	0.00178	0.00178	CbGeAlD
Bosutinib—MAP4K5—female reproductive system—fallopian tube cancer	0.00177	0.00177	CbGeAlD
Bosutinib—MAP3K3—female reproductive system—fallopian tube cancer	0.00177	0.00177	CbGeAlD
Bosutinib—RPS6KB1—vagina—fallopian tube cancer	0.00177	0.00177	CbGeAlD
Bosutinib—FGR—female gonad—fallopian tube cancer	0.00177	0.00177	CbGeAlD
Bosutinib—LCK—female gonad—fallopian tube cancer	0.00177	0.00177	CbGeAlD
Bosutinib—AXL—female gonad—fallopian tube cancer	0.00176	0.00176	CbGeAlD
Bosutinib—LCK—vagina—fallopian tube cancer	0.00176	0.00176	CbGeAlD
Bosutinib—FGR—vagina—fallopian tube cancer	0.00176	0.00176	CbGeAlD
Bosutinib—AXL—vagina—fallopian tube cancer	0.00175	0.00175	CbGeAlD
Bosutinib—MAP2K5—endometrium—fallopian tube cancer	0.00175	0.00175	CbGeAlD
Bosutinib—CSF1R—endometrium—fallopian tube cancer	0.0017	0.0017	CbGeAlD
Bosutinib—SLK—female gonad—fallopian tube cancer	0.00169	0.00169	CbGeAlD
Bosutinib—PDGFRB—epithelium—fallopian tube cancer	0.00168	0.00168	CbGeAlD
Bosutinib—SLK—vagina—fallopian tube cancer	0.00168	0.00168	CbGeAlD
Bosutinib—EPHB4—female gonad—fallopian tube cancer	0.00168	0.00168	CbGeAlD
Bosutinib—EPHB4—vagina—fallopian tube cancer	0.00167	0.00167	CbGeAlD
Bosutinib—PDGFRB—uterine cervix—fallopian tube cancer	0.00167	0.00167	CbGeAlD
Bosutinib—EPHA2—female gonad—fallopian tube cancer	0.00165	0.00165	CbGeAlD
Bosutinib—FYN—female gonad—fallopian tube cancer	0.00165	0.00165	CbGeAlD
Bosutinib—EPHA2—vagina—fallopian tube cancer	0.00164	0.00164	CbGeAlD
Bosutinib—FYN—vagina—fallopian tube cancer	0.00164	0.00164	CbGeAlD
Bosutinib—YES1—female reproductive system—fallopian tube cancer	0.00163	0.00163	CbGeAlD
Bosutinib—STK10—female reproductive system—fallopian tube cancer	0.00162	0.00162	CbGeAlD
Bosutinib—TAOK3—female reproductive system—fallopian tube cancer	0.00161	0.00161	CbGeAlD
Bosutinib—MAP3K3—female gonad—fallopian tube cancer	0.00161	0.00161	CbGeAlD
Bosutinib—MAP4K5—female gonad—fallopian tube cancer	0.00161	0.00161	CbGeAlD
Bosutinib—MAP3K3—vagina—fallopian tube cancer	0.0016	0.0016	CbGeAlD
Bosutinib—MAP4K5—vagina—fallopian tube cancer	0.0016	0.0016	CbGeAlD
Bosutinib—SRC—female reproductive system—fallopian tube cancer	0.00157	0.00157	CbGeAlD
Bosutinib—CSF1R—uterus—fallopian tube cancer	0.00157	0.00157	CbGeAlD
Bosutinib—PDGFRB—endometrium—fallopian tube cancer	0.00151	0.00151	CbGeAlD
Bosutinib—ABL1—uterine cervix—fallopian tube cancer	0.00149	0.00149	CbGeAlD
Bosutinib—YES1—female gonad—fallopian tube cancer	0.00149	0.00149	CbGeAlD
Bosutinib—YES1—vagina—fallopian tube cancer	0.00148	0.00148	CbGeAlD
Bosutinib—STK10—female gonad—fallopian tube cancer	0.00147	0.00147	CbGeAlD
Bosutinib—TAOK3—female gonad—fallopian tube cancer	0.00147	0.00147	CbGeAlD
Bosutinib—STK10—vagina—fallopian tube cancer	0.00146	0.00146	CbGeAlD
Bosutinib—TAOK3—vagina—fallopian tube cancer	0.00146	0.00146	CbGeAlD
Bosutinib—MAP2K5—female reproductive system—fallopian tube cancer	0.00145	0.00145	CbGeAlD
Bosutinib—SRC—female gonad—fallopian tube cancer	0.00143	0.00143	CbGeAlD
Bosutinib—CSF1R—female reproductive system—fallopian tube cancer	0.00141	0.00141	CbGeAlD
Bosutinib—PDGFRB—uterus—fallopian tube cancer	0.00139	0.00139	CbGeAlD
Bosutinib—ABL1—endometrium—fallopian tube cancer	0.00135	0.00135	CbGeAlD
Bosutinib—MAP2K5—female gonad—fallopian tube cancer	0.00132	0.00132	CbGeAlD
Bosutinib—MAP2K5—vagina—fallopian tube cancer	0.00131	0.00131	CbGeAlD
Bosutinib—CSF1R—female gonad—fallopian tube cancer	0.00128	0.00128	CbGeAlD
Bosutinib—CSF1R—vagina—fallopian tube cancer	0.00128	0.00128	CbGeAlD
Bosutinib—PDGFRB—female reproductive system—fallopian tube cancer	0.00125	0.00125	CbGeAlD
Bosutinib—ABL1—uterus—fallopian tube cancer	0.00124	0.00124	CbGeAlD
Bosutinib—PDGFRB—female gonad—fallopian tube cancer	0.00114	0.00114	CbGeAlD
Bosutinib—PDGFRB—vagina—fallopian tube cancer	0.00113	0.00113	CbGeAlD
Bosutinib—ABL1—female reproductive system—fallopian tube cancer	0.00112	0.00112	CbGeAlD
Bosutinib—ABL1—female gonad—fallopian tube cancer	0.00102	0.00102	CbGeAlD
Bosutinib—ABL1—vagina—fallopian tube cancer	0.00101	0.00101	CbGeAlD
Bosutinib—CYP3A4—female reproductive system—fallopian tube cancer	0.00049	0.00049	CbGeAlD
Bosutinib—ABCB1—epithelium—fallopian tube cancer	0.000467	0.000467	CbGeAlD
Bosutinib—ABCB1—uterine cervix—fallopian tube cancer	0.000463	0.000463	CbGeAlD
Bosutinib—ABCB1—endometrium—fallopian tube cancer	0.000419	0.000419	CbGeAlD
Bosutinib—ABCB1—uterus—fallopian tube cancer	0.000386	0.000386	CbGeAlD
Bosutinib—ABCB1—female reproductive system—fallopian tube cancer	0.000347	0.000347	CbGeAlD
Bosutinib—ABCB1—female gonad—fallopian tube cancer	0.000316	0.000316	CbGeAlD
Bosutinib—ABCB1—vagina—fallopian tube cancer	0.000314	0.000314	CbGeAlD
